https://somerville-partners.com/orphan-medicines-new-pharmaceutical-legislation/ 2026-08-19T09:02:19+00:00 https://somerville-partners.com/wp-content/uploads/2026/08/Pre-approval-regulatory-deliverables-and-how-the-new-pharmaceutical-legislation-will-affect-medicine-development.png https://somerville-partners.com/wp-content/uploads/2026/08/orphan-medicines-market-regulatory-exclusivity.png https://somerville-partners.com/what-is-project-optimus/ 2026-08-05T18:03:09+00:00 https://somerville-partners.com/regulatory-news-pharma-biotech-june-2026/ 2026-07-30T14:12:48+00:00 https://somerville-partners.com/regulatory-news-pharma-biotech-july-2026/ 2026-07-30T14:11:54+00:00 https://somerville-partners.com/what-are-the-challenges-with-project-optimus/ 2026-07-22T08:22:01+00:00 https://somerville-partners.com/project-optimus-the-oncology-dosing-issue/ 2026-07-09T08:42:00+00:00 https://somerville-partners.com/wp-content/uploads/2026/06/oncology-products-with-modified-dosing.png https://somerville-partners.com/regulatory-news-in-pharma-biotech-mar-2026/ 2026-06-23T19:59:29+00:00 https://somerville-partners.com/eu-uk-us-regulatory-approaches-orphan-drugs/ 2026-06-15T14:06:56+00:00 https://somerville-partners.com/wp-content/uploads/2026/01/orphan-medicines-financial-regulatory-incentives-1-e1768918852571.png https://somerville-partners.com/regulatory-roundup-news-publications-in-pharma-and-biotech-in-november-2025/ 2026-06-15T09:24:39+00:00 https://somerville-partners.com/regulatory-news-pharma-biotech-may-2026/ 2026-06-15T09:24:03+00:00 https://somerville-partners.com/regulatory-news-in-pharma-biotech-apr-2026/ 2026-06-15T09:23:37+00:00 https://somerville-partners.com/regulatory-news-in-pharma-biotech-feb-2026/ 2026-06-15T09:22:41+00:00 https://somerville-partners.com/regulatory-news-in-pharma-biotech-jan-2026/ 2026-06-15T09:21:51+00:00 https://somerville-partners.com/june-2025-regulatory-roundup-key-news-publications-in-pharma-and-biotech/ 2026-05-14T09:46:17+00:00 https://somerville-partners.com/july-2025-regulatory-roundup/ 2026-05-14T09:46:16+00:00 https://somerville-partners.com/october-regulatory-intelligence/ 2026-05-14T09:46:15+00:00 https://somerville-partners.com/august-2025-regulatory-roundup/ 2026-05-14T09:46:15+00:00 https://somerville-partners.com/biomarker-oncology-therapeutics-genome-cancer-sequencing/ 2026-05-14T09:44:40+00:00 https://somerville-partners.com/wp-content/uploads/2024/01/Precision_oncology_insights_from_genomes_cancer_programme.png https://somerville-partners.com/2023-ema-oncology-approvals/ 2026-05-14T09:44:32+00:00 https://somerville-partners.com/4-benefits-of-receiving-ema-scientific-advice/ 2026-05-14T09:44:05+00:00 https://somerville-partners.com/wp-content/uploads/2024/03/ema-scientific-advice-evaluation-timeline.png https://somerville-partners.com/how-the-ema-helps-smes/ 2026-05-14T09:44:04+00:00 https://somerville-partners.com/how-successful-are-the-emas-sme-initiatives/ 2026-05-14T09:44:04+00:00 https://somerville-partners.com/wp-content/uploads/2024/03/european-medicines-agency-sme-qualificaiton-process.png https://somerville-partners.com/wp-content/uploads/2024/03/european-medicines-agency-support-for-smes.png https://somerville-partners.com/wp-content/uploads/2024/03/european-medicines-agency-sme-challenges.png https://somerville-partners.com/challenges-pharmaceutical-smes-face/ 2026-05-14T09:44:03+00:00 https://somerville-partners.com/how-to-apply-for-sme-status-with-the-ema/ 2026-05-14T09:44:02+00:00 https://somerville-partners.com/wp-content/uploads/2024/03/categories-for-defining-an-sme.png https://somerville-partners.com/how-to-get-a-drug-approved-by-the-ema/ 2026-05-14T09:44:02+00:00 https://somerville-partners.com/wp-content/uploads/2023/01/SomervilleArtboard-5.png https://somerville-partners.com/wp-content/uploads/2023/01/SomervilleArtboard-5.png https://somerville-partners.com/wp-content/uploads/2023/01/SomervilleArtboard-5.png https://somerville-partners.com/wp-content/uploads/2023/01/SomervilleArtboard-5.png https://somerville-partners.com/wp-content/uploads/2025/08/ema-maa-pre-submission-guidelines.png https://somerville-partners.com/how-the-ema-evaluates-a-marketing-authorisation-application-maa/ 2026-05-14T09:44:01+00:00 https://somerville-partners.com/wp-content/uploads/2024/04/emas-marketing-authorisation-application-evaluation-process.png https://somerville-partners.com/what-are-regulatory-data-and-market-exclusivity-drug-approval-in-europe/ 2026-05-14T09:44:00+00:00 https://somerville-partners.com/wp-content/uploads/2025/08/maa-market-and-data-exclusivity-1.png https://somerville-partners.com/wp-content/uploads/2025/08/maa-data-exclusivity-market-protection-orphan-medicines.png https://somerville-partners.com/wp-content/uploads/2025/08/maa-data-exclusivity-market-protection-pip.png https://somerville-partners.com/marketing-authorisation-application-ema-vs-new-drug-application-fda/ 2026-05-14T09:43:59+00:00 https://somerville-partners.com/wp-content/uploads/2024/07/ema-evaluation-timeline-maa.png https://somerville-partners.com/wp-content/uploads/2025/08/types-of-fda-meetings-medicine-approval.png https://somerville-partners.com/genome-editing-medicines-a-shifting-regulatory-landscape/ 2026-05-14T09:43:59+00:00 https://somerville-partners.com/wp-content/uploads/2025/08/who-framework-human-genome-editing.png https://somerville-partners.com/what-is-the-pre-cta-scientific-advice-pilot-programme/ 2026-05-14T09:43:58+00:00 https://somerville-partners.com/wp-content/uploads/2024/12/pre-cta-advice-process.png https://somerville-partners.com/what-has-changed-in-the-priority-medicines-prime-scheme/ 2026-05-14T09:43:57+00:00 https://somerville-partners.com/wp-content/uploads/2025/08/prime-scheme-benefits-for-medicine-developers.png https://somerville-partners.com/wp-content/uploads/2025/08/prime-scheme-eligibility-scope-and-timing.png https://somerville-partners.com/the-emas-new-fees-what-does-the-new-fee-regulation-mean-for-medicine-developers/ 2026-05-14T09:43:57+00:00 https://somerville-partners.com/wp-content/uploads/2024/12/scientific-advice-fee-levels.png https://somerville-partners.com/wp-content/uploads/2024/12/paediatric-development-fees.png https://somerville-partners.com/wp-content/uploads/2024/12/orphan-medicines-fee-reductions.png https://somerville-partners.com/how-the-emas-revised-ctis-transparency-rules-affect-clinical-trial-sponsors/ 2026-05-14T09:43:56+00:00 https://somerville-partners.com/wp-content/uploads/2025/12/clinical-trial-regulation-transparency-rules.png https://somerville-partners.com/european-clinical-trials-after-the-ctd-to-ctr-transition/ 2026-05-14T09:43:56+00:00 https://somerville-partners.com/the-blenrep-belantamab-mafodotin-blmf-story-in-multiple-myeloma/ 2026-05-14T09:40:39+00:00 https://somerville-partners.com/an-overview-of-the-medicines-and-healthcare-products-agency-mhra-innovative-licensing-and-access-pathway-ilap/ 2026-05-09T16:02:45+00:00 https://somerville-partners.com/wp-content/uploads/2025/02/criteria-for-ILAP-Innovation-Passport.png https://somerville-partners.com/wp-content/uploads/2025/08/ilap-target-development-profile-tdp.png https://somerville-partners.com/national-scientific-advice-vs-ema-scientific-advice/ 2026-05-09T16:02:04+00:00 https://somerville-partners.com/wp-content/uploads/2024/12/scientific-advice-questions-at-different-development-stages.png https://somerville-partners.com/wp-content/uploads/2024/12/scientific-advice-process.png https://somerville-partners.com/wp-content/uploads/2024/12/scientific-advice-evaluation-timelines.png https://somerville-partners.com/mhra-ilap-relaunch-2025-accelerating-access-to-innovative-medicines-in-the-uk/ 2026-05-09T16:01:29+00:00 https://somerville-partners.com/wp-content/uploads/2025/08/updated-ilap-eligibility-criteria.png https://somerville-partners.com/novel-medicines-approved-in-2024-a-review/ 2026-05-09T16:01:10+00:00 https://somerville-partners.com/the-uks-post-brexit-orphan-drug-strategy/ 2026-04-17T08:58:23+00:00 https://somerville-partners.com/regulatory-roundup-news-publications-in-pharma-and-biotech-in-december-2025/ 2026-03-11T09:56:38+00:00 https://somerville-partners.com/september-2025-regulatory-roundup/ 2026-03-11T09:56:31+00:00 https://somerville-partners.com/the-medicines-and-healthcare-products-agency-mhra-has-relaunched-its-innovative-licensing-and-access-pathway-ilap/ 2026-03-11T09:56:14+00:00 https://somerville-partners.com/wp-content/uploads/2025/08/mhra-ilap-improvements-2025.png https://somerville-partners.com/module-1-of-the-marketing-authorisation-application-dossier/ 2026-03-11T09:56:12+00:00 https://somerville-partners.com/wp-content/uploads/2025/08/module-1-documents-in-the-ctd-1.png https://somerville-partners.com/wp-content/uploads/2024/08/maa-module-1-2.png https://somerville-partners.com/gene-editing-medicinal-products-the-first-ema-approval/ 2026-03-11T09:56:04+00:00 https://somerville-partners.com/fdas-benefit-risk-framework-new-guidance/ 2026-03-11T09:55:53+00:00 https://somerville-partners.com/wp-content/uploads/2025/08/fda-benefit-risk-framework.png https://somerville-partners.com/international-recognition-procedure-new-medicine-approval-in-2-4-months/ 2026-03-11T09:55:51+00:00 https://somerville-partners.com/wp-content/uploads/2025/08/how-to-apply-for-the-international-recognition-procedure.png https://somerville-partners.com/wp-content/uploads/2025/08/irp-approval-routes-comparison.png